Heroic

autumn @newlimit -- we've advanced our 1st reprogramming medicine through optimization highlights - 8X specificity, 1.6X potency for our lead prototype medicine - +2 TF sets that restore liver function, +20 that restore phenotype - 0 -> 1 preclinical models of endothelial age # engineering therapeutic molecules in september, we selected our first prototype medicine for liver aging to advance toward the clinic. this initiated our first lead optimization campaign to improve the potency & specificity of our prototype. our RNA medicines allow for engineering at the sequence level. RNAs are not translated into proteins equally across cell types, and we can design sequences to maximize activity in our target cells (hepatocytes) and minimize activity elsewhere. our campaign achieved an 8X increase in the specificity of our prototype & a 1.6X increase in the potency within hepatocytes. we believe these optimizations will yield a safer, more effective medicine. # restoring youthful resilience alongside progressing our first asset, we've continued to discover reprogramming payloads that restore youthful function. in october, we discovered +2 payloads that restore youthful resilience to alcohol damage in old livers. these payloads emerged from our discovery screens & validated as prototype RNA medicines. each month, more of these payloads emerge from Discovery Engine, giving us confidence that the well of potential reprogramming medicines is deep. # in vivo T cell reprogramming hepatic reprogramming is only one of several therapeutic applications we’re pursuing. we’ve previously discovered reprogramming payloads that restore youthful cytotoxic capacity and stem-like states to old human T cells. the next stage in the development of these payloads is to test whether they can rescue function in a more complex animal model. before we can test their effects directly, we need to build molecular tools to deliver reprogramming payloads to T cells in vivo. after a series of engineering iterations, we've developed a lipid chemistry that can carry our RNA medicines into T cells in animals. our chemistry is now nearly matching the current state-of-the-art. # measuring endothelial cell age our most recent therapeutic program is focused on restoring function in endothelial cells of the vasculature. we believe improving endothelial function could create renal, cardiovascular, and cognitive health. endothelial cell aging is dramatic enough that we’ve been able to discover functional impairments in just our first few experiments. human endothelial cells are less regenerative in simple in vitro systems, and endothelial injury leads to more dramatic renal damage in old animals. even these early tools allow us to start testing the effect of reprogramming on aged endothelial function, in addition to phenotypes. # join our team we're recruiting talented scientists & engineers across our therapeutic programs and technology teams. reach out if you're excited to create a new class of medicines that add healthy, happy years for ~everyone.

Biochemist @CharlesMBrenner is calling BS on scientists who claim to be able to extend human lifespan. So who is right? nautil.us/the-longevity-…

While elevated levels of LDL is known for heart disease, few know about Lp(a) risks. Elevated Lp(a) is an independent risk factor for cardiovascular disease. It should be detected early to help prevent CVD. Learn more: bit.ly/49GXYN4 #LpaAwarenessDay #FHEurope

Biden wants to replace lead pipes. He failed to mention that the unfunded mandate sets an almost impossible timeline, will cost billions, infringe on the rights of the States and their residents – all for benefits that may be entirely speculative. #sotu ag.ks.gov/media-center/n…